PLYMOUTH
MEETING, Pa., Oct. 16,
2024 /PRNewswire/ -- Harmony Biosciences Holdings,
Inc. (Nasdaq: HRMY) today announced that it will report third
quarter 2024 financial results on Tuesday,
October 29, 2024, before the open of the U.S. financial
markets. Harmony will host a conference call and webcast on
October 29, 2024, at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial (800) 245-3047
(domestic) or (203) 518-9765 (international), and reference
passcode HRMYQ324. It is recommended that you dial in at least 10
minutes prior to the call.
The live and replay webcast of the call will be available on the
investor page of our website
at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony Biosciences is a
pharmaceutical company dedicated to developing and commercializing
innovative therapies for patients with rare neurological diseases
who have unmet medical needs. Driven by novel science, visionary
thinking, and a commitment to those who feel overlooked, Harmony
Biosciences is nurturing a future full of therapeutic possibilities
that may enable patients with rare neurological diseases to truly
thrive. Established by Paragon Biosciences, LLC, in 2017 and
headquartered in Plymouth Meeting,
PA, we believe that when empathy and innovation meet, a
better future can begin; a vision evident in the therapeutic
innovations we advance, the culture we cultivate, and the community
programs we foster. For more information, please visit
www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-report-third-quarter-2024-financial-results-on-october-29-2024-302277106.html
SOURCE Harmony Biosciences